Brainstorm Cell Therapeutics Inc.
BCLI
$1.20
-$0.02-1.64%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -11.09M | -11.62M | -14.23M | -12.75M | -15.53M |
| Total Depreciation and Amortization | 228.00K | 240.00K | 253.00K | 259.00K | 262.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 768.00K | 221.00K | 6.86M | 2.86M | 3.66M |
| Change in Net Operating Assets | 2.43M | 2.07M | -4.21M | -4.82M | -7.92M |
| Cash from Operations | -7.66M | -9.09M | -11.33M | -14.44M | -19.54M |
| Capital Expenditure | -- | -- | -18.00K | -18.00K | -18.00K |
| Sale of Property, Plant, and Equipment | 12.00K | 12.00K | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | 214.00K | 202.00K | 206.00K |
| Cash from Investing | 12.00K | 12.00K | 196.00K | 184.00K | 188.00K |
| Total Debt Issued | 900.00K | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 6.11M | 7.97M | 10.26M | 17.36M | 18.29M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 1.50M | -- | -- | -- | -- |
| Cash from Financing | 8.51M | 7.97M | 10.26M | 17.36M | 18.29M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 865.00K | -1.11M | -873.00K | 3.10M | -1.06M |